Imunon (NASDAQ:IMNN) Upgraded by EF Hutton Acquisition Co. I to “Strong-Buy”

EF Hutton Acquisition Co. I upgraded shares of Imunon (NASDAQ:IMNN) to a strong-buy rating in a research report released on Monday, Zacks.com reports.

Separately, HC Wainwright reiterated a buy rating and issued a $14.00 price target on shares of Imunon in a research report on Thursday, August 15th.

Imunon Stock Performance

Shares of Imunon stock opened at $1.01 on Monday. The firm has a fifty day moving average of $1.19 and a two-hundred day moving average of $1.26. The stock has a market capitalization of $9.50 million, a price-to-earnings ratio of -0.50 and a beta of 2.13. Imunon has a 52 week low of $0.48 and a 52 week high of $3.65.

Imunon (NASDAQ:IMNN) last released its quarterly earnings data on Wednesday, August 14th. The company reported ($0.51) EPS for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.04. As a group, research analysts forecast that Imunon will post -1.71 EPS for the current fiscal year.

Imunon Company Profile

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.